Osteoporosis International

, Volume 22, Issue 7, pp 2107–2118 | Cite as

Vitamin D in organ transplantation

Review

Abstract

Vitamin D deficiency is prevalent among patients with end-stage organ failure awaiting transplant. Low serum 25-hydroxyvitamin D (25-OHD) levels in these patients may be related to many disease-specific factors, as well as decreased sunlight exposure and limited intake of foods containing vitamin D. Low serum 25-OHD levels are also extremely common following solid organ transplantation, both during the immediate postoperative period and in long-term graft recipients. Demographic and lifestyle factors are important in determining D status in transplant recipients. Worse vitamin D status is associated with poorer general health, lower albumin, and even decreased survival among these patients. Although several studies have demonstrated that active forms of vitamin D and its analogues prevent bone loss following transplantation, the data do not show consistent benefit. These therapies may have particular utility after renal transplantation. However, given the narrow therapeutic window with respect to hypercalcemia and hypercalciuria, and the demonstrated efficacy of bisphosphonates to prevent post-transplantation bone loss, we regard these agents as adjunctive rather than primary therapy for transplantation osteoporosis. The effects of 1,25(OH)2D on the immune system, which are still being elucidated, may have potential for reducing infections and preventing allograft rejection after transplantation.

Keywords

Bone loss Fracture Organ transplantation Osteoporosis Vitamin D deficiency 

Notes

Conflicts of interest

None.

References

  1. 1.
    Dhesi JK, Bearne LM, Moniz C, Hurley MV, Jackson SH, Swift CG, Allain TJ (2002) Neuromuscular and psychomotor function in elderly subjects who fall and the relationship with vitamin D status. J Bone Miner Res 17:891–897PubMedCrossRefGoogle Scholar
  2. 2.
    Bischoff-Ferrari HA, Dawson-Hughes B, Willett WC, Staehelin HB, Bazemore MG, Zee RY, Wong JB (2004) Effect of Vitamin D on falls: a meta-analysis. JAMA 291:1999–2006PubMedCrossRefGoogle Scholar
  3. 3.
    Vieth R (1999) Vitamin D supplementation, 25-hydroxyvitamin D concentrations, and safety. Am J Clin Nutr 69:842–856PubMedGoogle Scholar
  4. 4.
    Holick MF (2007) Vitamin D deficiency. N Engl J Med 357:266–281PubMedCrossRefGoogle Scholar
  5. 5.
    Lemire JM (1995) Immunomodulatory actions of 1,25-dihydroxyvitamin D3. J Steroid Biochem Mol Biol 53:599–602PubMedCrossRefGoogle Scholar
  6. 6.
    Armas LA, Hollis BW, Heaney RP (2004) Vitamin D2 is much less effective than vitamin D3 in humans. J Clin Endocrinol Metab 89:5387–5391PubMedCrossRefGoogle Scholar
  7. 7.
    Holick MF, Biancuzzo RM, Chen TC, Klein EK, Young A, Bibuld D, Reitz R, Salameh W, Ameri A, Tannenbaum AD (2008) Vitamin D2 is as effective as vitamin D3 in maintaining circulating concentrations of 25-hydroxyvitamin D. J Clin Endocrinol Metab 93:677–681PubMedCrossRefGoogle Scholar
  8. 8.
    Trang HM, Cole DE, Rubin LA, Pierratos A, Siu S, Vieth R (1998) Evidence that vitamin D3 increases serum 25-hydroxyvitamin D more efficiently than does vitamin D2. Am J Clin Nutr 68:854–858PubMedGoogle Scholar
  9. 9.
    Shane E, Mancini D, Aaronson K, Silverberg SJ, Seibel MJ, Addesso V, McMahon DJ (1997) Bone mass, vitamin D deficiency and hyperparathyroidism in congestive heart failure. Am J Med 103:197–207PubMedCrossRefGoogle Scholar
  10. 10.
    Shane E, Silverberg SJ, Donovan D, Papadopoulos A, Staron RB, Addesso V, Jorgensen B, McGregor C, Shulman L (1996) Osteoporosis in lung transplantation candidates with end stage pulmonary disease. Am J Med 101:262–269PubMedCrossRefGoogle Scholar
  11. 11.
    Monegal A, Navasa M, Guanabens N, Peris P, Pons F, Martinez de Osaba MJ, Ordi J, Rimola A, Rodes J, Munoz-Gomez J (2001) Bone disease after liver transplantation: a long-term prospective study of bone mass changes, hormonal status and histomorphometric characteristics. Osteoporos Int 12:484–492PubMedCrossRefGoogle Scholar
  12. 12.
    Compston J, Greer S, Skingle S, Stirling D, Price C, Friend P, Alexander G (1996) Early increase in plasma parathyroid hormone level following liver transplantation. J Hepatol 25:715–718PubMedCrossRefGoogle Scholar
  13. 13.
    Stavroulopoulos A, Porter CJ, Roe SD, Hosking DJ, Cassidy MJ (2008) Relationship between vitamin D status, parathyroid hormone levels and bone mineral density in patients with chronic kidney disease stages 3 and 4. Nephrol (Carlton) 13:63–67Google Scholar
  14. 14.
    LaClair RE, Hellman RN, Karp SL, Kraus M, Ofner S, Li Q, Graves KL, Moe SM (2005) Prevalence of calcidiol deficiency in CKD: a cross-sectional study across latitudes in the United States. Am J Kidney Dis 45:1026–1033PubMedCrossRefGoogle Scholar
  15. 15.
    Zittermann A, Schleithoff SS, Gotting C, Dronow O, Fuchs U, Kuhn J, Kleesiek K, Tenderich G, Koerfer R (2008) Poor outcome in end-stage heart failure patients with low circulating calcitriol levels. Eur J Heart Fail 10:321–327PubMedCrossRefGoogle Scholar
  16. 16.
    Tschopp O, Schmid C, Speich R, Seifert B, Russi EW, Boehler A (2006) Pretransplantation bone disease in patients with primary pulmonary hypertension. Chest 129:1002–1008PubMedCrossRefGoogle Scholar
  17. 17.
    Tschopp O, Boehler A, Speich R, Weder W, Seifert B, Russi EW, Schmid C (2002) Osteoporosis before lung transplantation: association with low body mass index, but not with underlying disease. Am J Transplant 2:167–172PubMedCrossRefGoogle Scholar
  18. 18.
    Aris RM, Renner JB, Winders AD, Buell HE, Riggs DB, Lester GE, Ontjes DA (1998) Increased rate of fractures and severe kyphosis: sequelae of living into adulthood with cystic fibrosis. Ann Intern Med 128:186–193PubMedGoogle Scholar
  19. 19.
    Donovan DS Jr, Papadopoulos A, Staron RB, Addesso V, Schulman L, McGregor C, Cosman F, Lindsay RL, Shane E (1998) Bone mass and vitamin D deficiency in adults with advanced cystic fibrosis lung disease. Am J Respir Crit Care Med 157:1892–1899PubMedGoogle Scholar
  20. 20.
    Ott SM, Aitken ML (1998) Osteoporosis in patients with cystic fibrosis. Clin Chest Med 19:555–567PubMedCrossRefGoogle Scholar
  21. 21.
    Forli L, Bjortuft O, Boe J (2009) Vitamin D status in relation to nutritional depletion and muscle function in patients with advanced pulmonary disease. Exp Lung Res 35:524–538PubMedCrossRefGoogle Scholar
  22. 22.
    Monegal A, Navasa M, Guanabens N, Peris P, Pons F, MJMd O, Rimola A, Rodes J, Munoz-Gomez J (1997) Osteoporosis and bone mineral metabolism in cirrhotic patients referred for liver transplantation. Calcif Tissue Int 60:148–154PubMedCrossRefGoogle Scholar
  23. 23.
    Bitetto D, Fabris C, Falleti E, Fornasiere E, Fumolo E, Fontanini E, Cussigh A, Occhino G, Baccarani U, Pirisi M, Toniutto P (2010) Vitamin D and the risk of acute allograft rejection following human liver transplantation. Liver Int 30:417–444PubMedCrossRefGoogle Scholar
  24. 24.
    Hruska KA, Matthew S (2008) Chronic kidney disease mineral bone disorder (CKD-MBD). In: Rosen C (ed) Primer on the metabolic bone diseases and disorders of mineral metabolism. American Society for Bone and Mineral Research, Washington, pp 343–348CrossRefGoogle Scholar
  25. 25.
    Ishimura E, Nishizawa Y, Inaba M, Matsumoto N, Emoto M, Kawagishi T, Shoji S, Okuno S, Kim M, Miki T, Morii H (1999) Serum levels of 1,25-dihydroxyvitamin D, 24,25-dihydroxyvitamin D, and 25-hydroxyvitamin D in nondialyzed patients with chronic renal failure. Kidney Int 55:1019–1027PubMedCrossRefGoogle Scholar
  26. 26.
    Ravani P, Malberti F, Tripepi G, Pecchini P, Cutrupi S, Pizzini P, Mallamaci F, Zoccali C (2009) Vitamin D levels and patient outcome in chronic kidney disease. Kidney Int 75:88–95PubMedCrossRefGoogle Scholar
  27. 27.
    Teng M, Wolf M, Lowrie E, Ofsthun N, Lazarus JM, Thadhani R (2003) Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N Engl J Med 349:446–456PubMedCrossRefGoogle Scholar
  28. 28.
    Teng M, Wolf M, Ofsthun MN, Lazarus JM, Hernan MA, Camargo CA Jr, Thadhani R (2005) Activated injectable vitamin D and hemodialysis survival: a historical cohort study. J Am Soc Nephrol 16:1115–1125PubMedCrossRefGoogle Scholar
  29. 29.
    Kovesdy CP, Ahmadzadeh S, Anderson JE, Kalantar-Zadeh K (2008) Association of activated vitamin D treatment and mortality in chronic kidney disease. Arch Intern Med 168:397–403PubMedCrossRefGoogle Scholar
  30. 30.
    Stein EM, Cohen A, Freeby M, Rogers H, Kokolus S, Scott V, Mancini D, Restaino S, Brown R, McMahon DJ, Shane E (2009) Severe vitamin D deficiency among heart and liver transplant recipients. Clin Transplant 23:861–865PubMedCrossRefGoogle Scholar
  31. 31.
    Querings K, Girndt M, Geisel J, Georg T, Tilgen W, Reichrath J (2006) 25-Hydroxyvitamin D deficiency in renal transplant recipients. J Clin Endocrinol Metab 91:526–529PubMedCrossRefGoogle Scholar
  32. 32.
    Segal E, Baruch Y, Kramsky R, Raz B, Ish-Shalom S (2001) Vitamin D deficiency in liver transplant patients in Israel. Transplant Proc 33:2955–2956PubMedCrossRefGoogle Scholar
  33. 33.
    Ewers B, Gasbjerg A, Moelgaard C, Frederiksen AM, Marckmann P (2008) Vitamin D status in kidney transplant patients: need for intensified routine supplementation. Am J Clin Nutr 87:431–437PubMedGoogle Scholar
  34. 34.
    Tripathi SS, Gibney EM, Gehr TW, King AL, Beckman MJ (2008) High prevalence of vitamin D deficiency in African American kidney transplant recipients. Transplantation 85:767–770PubMedCrossRefGoogle Scholar
  35. 35.
    Lips P, Chapuy MC, Dawson-Hughes B, Pols HA, Holick MF (1999) An international comparison of serum 25-hydroxyvitamin D measurements. Osteoporos Int 9:394–397PubMedCrossRefGoogle Scholar
  36. 36.
    Binkley N, Krueger D, Cowgill CS, Plum L, Lake E, Hansen KE, DeLuca HF, Drezner MK (2004) Assay variation confounds the diagnosis of hypovitaminosis D: a call for standardization. J Clin Endocrinol Metab 89:3152–3157PubMedCrossRefGoogle Scholar
  37. 37.
    Glendenning P, Noble JM, Taranto M, Musk AA, McGuiness M, Goldswain PR, Fraser WD, Vasikaran SD (2003) Issues of methodology, standardization and metabolite recognition for 25-hydroxyvitamin D when comparing the DiaSorin radioimmunoassay and the Nichols Advantage automated chemiluminescence protein-binding assay in hip fracture cases. Ann Clin Biochem 40:546–551PubMedCrossRefGoogle Scholar
  38. 38.
    Reichrath J (2010) Dermatologic management, sun avoidance and vitamin D status in organ transplant recipients (OTR). J Photochem Photobiol B 101:150–159PubMedCrossRefGoogle Scholar
  39. 39.
    Courbebaisse M, Souberbielle JC, Thervet E (2010) Potential nonclassical effects of vitamin D in transplant recipients. Transplantation 89:131–137PubMedCrossRefGoogle Scholar
  40. 40.
    Akeno N, Matsunuma A, Maeda T, Kawane T, Horiuchi N (2000) Regulation of vitamin D-1alpha-hydroxylase and -24-hydroxylase expression by dexamethasone in mouse kidney. J Endocrinol 164:339–348PubMedCrossRefGoogle Scholar
  41. 41.
    Pascussi JM, Robert A, Nguyen M, Walrant-Debray O, Garabedian M, Martin P, Pineau T, Saric J, Navarro F, Maurel P, Vilarem MJ (2005) Possible involvement of pregnane X receptor-enhanced CYP24 expression in drug-induced osteomalacia. J Clin Invest 115:177–186PubMedGoogle Scholar
  42. 42.
    Giannini S, Sella S, Netto FS, Cattelan C, Dalle Carbonare L, Lazzarin R, Marchini F, Rigotti P, Marcocci C, Cetani F, Pardi E, D’Angelo A, Realdi G, Bonfante L (2010) Persistent secondary hyperparathyroidism and vertebral fractures in kidney transplantation: role of calcium-sensing receptor polymorphisms and vitamin D deficiency. J Bone Miner Res 25:841–848PubMedGoogle Scholar
  43. 43.
    Sadlier DM, Magee CC (2007) Prevalence of 25(OH) vitamin D (calcidiol) deficiency at time of renal transplantation: a prospective study. Clin Transplant 21:683–688PubMedGoogle Scholar
  44. 44.
    Marcen R, Ponte B, Rodriguez-Mendiola N, Fernandez-Rodriguez A, Galeano C, Villafruela JJ, Teruel JL, Burgos FJ, Ortuno J (2009) Vitamin D deficiency in kidney transplant recipients: risk factors and effects of vitamin D3 supplements. Transplant Proc 41:2388–2390PubMedCrossRefGoogle Scholar
  45. 45.
    Lynch IT, Eustace JA, Plant WD, Cashman KD, O’Keefe M, Lordan S, Moloney R (2007) Inadequate dietary calcium and vitamin D intakes in renal-transplant recipients in Ireland. J Ren Nutr 17:408–415PubMedCrossRefGoogle Scholar
  46. 46.
    Sezer S, Yavuz D, Canoz MB, Ozdemir FN, Haberal M (2009) Vitamin D status, bone mineral density, and inflammation in kidney transplantation patients. Transplant Proc 41:2823–2825PubMedCrossRefGoogle Scholar
  47. 47.
    Bhan I, Shah A, Holmes J, Isakova T, Gutierrez O, Burnett SM, Juppner H, Wolf M (2006) Post-transplant hypophosphatemia: tertiary ‘hyper-phosphatoninism’? Kidney Int 70:1486–1494PubMedCrossRefGoogle Scholar
  48. 48.
    Sambrook PN, Kelly PJ, Fontana D, Nguyen T, Keogh A, Macdonald D, Spratt P, Freund J, Eisman JA (1994) Mechanisms of rapid bone loss following cardiac transplantation. Osteoporos Int 4:273–276PubMedCrossRefGoogle Scholar
  49. 49.
    Shane E, Rivas M, McMahon DJ, Staron RB, Silverberg SJ, Seibel MJ, Mancini D, Michler R, Aaronson K, Addesso V, Lo SH (1997) Bone loss and turnover after cardiac transplantation. J Clin Endocrinol Metab 82:1497–1506PubMedCrossRefGoogle Scholar
  50. 50.
    Valimaki MJ, Kinnunen K, Tahtela R, Loyttyniemi E, Laitinen K, Makela P, Keto P, Nieminen M (1999) A prospective study of bone loss and turnover after cardiac transplantation: effect of calcium supplementation with or without calcitonin. Osteoporos Int 10:128–136PubMedCrossRefGoogle Scholar
  51. 51.
    Zittermann A, Schleithoff SS, Gotting C, Fuchs U, Kuhn J, Kleesiek K, Tenderich G, Koerfer R (2009) Calcitriol deficiency and 1-year mortality in cardiac transplant recipients. Transplantation 87:118–124PubMedCrossRefGoogle Scholar
  52. 52.
    Segal E, Baruch Y, Kramsky R, Raz B, Tamir A, Ish-Shalom S (2003) Predominant factors associated with bone loss in liver transplant patients—after prolonged post-transplantation period. Clin Transplant 17:13–19PubMedCrossRefGoogle Scholar
  53. 53.
    Guichelaar MM, Kendall R, Malinchoc M, Hay JE (2006) Bone mineral density before and after OLT: long-term follow-up and predictive factors. Liver Transplant 12:1390–1402CrossRefGoogle Scholar
  54. 54.
    Floreani A, Mega A, Tizian L, Burra P, Boccagni P, Baldo V, Fagiuoli S, Naccarato R, Luisetto G (2001) Bone metabolism and gonad function in male patients undergoing liver transplantation: a two-year longitudinal study. Osteoporos Int 12:749–754PubMedCrossRefGoogle Scholar
  55. 55.
    Hawkins FG, Leon M, Lopez MB, Valero MA, Larrodera L, Garcia-Garcia I, Loinaz C, Gonzales EM (1994) Bone loss and turnover in patients with liver transplantation. Hepato Gastroenterol 41:158–161Google Scholar
  56. 56.
    Meys E, Fontanges E, Fourcade N, Thomasson A, Pouyet M, Delmas P (1994) Bone loss after orthotopic liver transplantation. Am J Med 97:445–450PubMedCrossRefGoogle Scholar
  57. 57.
    Valero M, Loinaz C, Larrodera L, Leon M, Morena E, Hawkins F (1995) Calcitonin and bisphosphonate treatment in bone loss after liver transplantation. Calcif Tissue Int 57:15–19PubMedCrossRefGoogle Scholar
  58. 58.
    Sambrook P (1999) Alfacalcidol and calcitriol in the prevention of bone loss after organ transplantation. Calcif Tissue Int 65:341–343PubMedCrossRefGoogle Scholar
  59. 59.
    Briffa NK, Keogh AM, Sambrook PN, Eisman JA (2003) Reduction of immunosuppressant therapy requirement in heart transplantation by calcitriol. Transplantation 75:2133–2134PubMedCrossRefGoogle Scholar
  60. 60.
    Lemire JM (1992) Immunomodulatory role of 1,25 dihydroxyvitamin D3. J Cell Biochem 49:26–31PubMedCrossRefGoogle Scholar
  61. 61.
    Lemire JM, Archer DC, Reddy GS (1994) Dihydroxy-24-oxo-16-ene-vitamin D3, a renal metabolite of the vitamin D analog 1, 25-dihydroxy-16ene-vitamin D3, exerts immunosuppressive activity equal to its parent without causing hypercalcemia in vivo. Endocrinology 135:2818–2821PubMedCrossRefGoogle Scholar
  62. 62.
    Shane E, Addesso V, Namerow PB, McMahon DJ, Lo SH, Staron RB, Zucker M, Pardi S, Maybaum S, Mancini D (2004) Alendronate versus calcitriol for the prevention of bone loss after cardiac transplantation. N Engl J Med 350:767–776PubMedCrossRefGoogle Scholar
  63. 63.
    Krieg MA, Seydoux C, Sandini L, Goy JJ, Berguer DG, Thiebaud D, Burckhardt P (2001) Intravenous pamidronate as treatment for osteoporosis after heart transplantation: a prospective study. Osteoporos Int 12:112–116PubMedCrossRefGoogle Scholar
  64. 64.
    Henderson K, Eisman J, Keogh A, MacDonald P, Glanville A, Spratt P, Sambrook P (2001) Protective effect of short-term calcitriol or cyclical etidronate on bone loss after cardiac or lung transplantation. J Bone Miner Res 16:565–571PubMedCrossRefGoogle Scholar
  65. 65.
    Shane E, Papadopoulos A, Staron RB, Addesso V, Donovan D, McGregor C, Schulman LL (1999) Bone loss and fracture after lung transplantation. Transplantation 68:220–227PubMedCrossRefGoogle Scholar
  66. 66.
    Al-Gabri S, Zadrazil J, Krejci K, Horak P, Bachleda P (2005) Changes in bone mineral density and selected metabolic parameters over 24 months following renal transplantation. Transplant Proc 37:1014–1019PubMedCrossRefGoogle Scholar
  67. 67.
    Wissing KM, Broeders N, Moreno-Reyes R, Gervy C, Stallenberg B, Abramowicz D (2005) A controlled study of vitamin D3 to prevent bone loss in renal-transplant patients receiving low doses of steroids. Transplantation 79:108–115PubMedCrossRefGoogle Scholar
  68. 68.
    Garcia-Delgado I, Prieto S, Gil-Fraguas L, Robles E, Rufilanchas JJ, Hawkins F (1997) Calcitonin, etidronate, and calcidiol treatment in bone loss after cardiac transplantation. Calcif Tissue Int 60:155–159PubMedCrossRefGoogle Scholar
  69. 69.
    El-Agroudy AE, El-Husseini AA, El-Sayed M, Ghoneim MA (2003) Preventing bone loss in renal transplant recipients with vitamin D. J Am Soc Nephrol 14:2975–2979PubMedCrossRefGoogle Scholar
  70. 70.
    De Sevaux RG, Hoitsma AJ, Corstens FH, Wetzels JF (2002) Treatment with vitamin D and calcium reduces bone loss after renal transplantation: a randomized study. J Am Soc Nephrol 13:1608–1614PubMedCrossRefGoogle Scholar
  71. 71.
    El-Agroudy AE, El-Husseini AA, El-Sayed M, Mohsen T, Ghoneim MA (2005) A prospective randomized study for prevention of postrenal transplantation bone loss. Kidney Int 67:2039–2045PubMedCrossRefGoogle Scholar
  72. 72.
    Fleseriu M, Licata AA (2007) Failure of successful renal transplant to produce appropriate levels of 1,25-dihydroxyvitamin D. Osteoporos Int 18:363–368PubMedCrossRefGoogle Scholar
  73. 73.
    Uyar M, Sezer S, Arat Z, Elsurer R, Ozdemir FN, Haberal M (2006) 1,25-Dihydroxyvitamin D(3) therapy is protective for renal function and prevents hyperparathyroidism in renal allograft recipients. Transplant Proc 38:2069–2073PubMedCrossRefGoogle Scholar
  74. 74.
    Josephson MA, Schumm LP, Chiu MY, Marshall C, Thistlethwaite JR, Sprague SM (2004) Calcium and calcitriol prophylaxis attenuates posttransplant bone loss. Transplantation 78:1233–1236PubMedCrossRefGoogle Scholar
  75. 75.
    Torres A, Garcia S, Gomez A, Gonzalez A, Barrios Y, Concepcion MT, Hernandez D, Garcia JJ, Checa MD, Lorenzo V, Salido E (2004) Treatment with intermittent calcitriol and calcium reduces bone loss after renal transplantation. Kidney Int 65:705–712PubMedCrossRefGoogle Scholar
  76. 76.
    Sambrook P, Henderson NK, Keogh A, MacDonald P, Glanville A, Spratt P, Bergin P, Ebeling P, Eisman J (2000) Effect of calcitriol on bone loss after cardiac or lung transplantation. J Bone Miner Res 15:1818–1824PubMedCrossRefGoogle Scholar
  77. 77.
    Cohen A, Addesso V, McMahon DJ, Staron RB, Namerow P, Maybaum S, Mancini D, Shane E (2006) Discontinuing antiresorptive therapy one year after cardiac transplantation: effect on bone density and bone turnover. Transplantation 81:686–691PubMedCrossRefGoogle Scholar
  78. 78.
    Cueto-Manzano AM, Konel S, Freemont AJ, Adams JE, Mawer B, Gokal R, Hutchison AJ (2000) Effect of 1,25-dihydroxyvitamin D3 and calcium carbonate on bone loss associated with long-term renal transplantation. Am J Kidney Dis 35:227–236PubMedCrossRefGoogle Scholar
  79. 79.
    Stempfle HU, Werner C, Siebert U, Assum T, Wehr U, Rambeck WA, Meiser B, Theisen K, Gartner R (2002) The role of tacrolimus (FK506)-based immunosuppression on bone mineral density and bone turnover after cardiac transplantation: a prospective, longitudinal, randomized, double-blind trial with calcitriol. Transplantation 73:547–552PubMedCrossRefGoogle Scholar
  80. 80.
    Stempfle HU, Werner C, Echtler S, Wehr U, Rambeck WA, Siebert U, Uberfuhr P, Angermann CE, Theisen K, Gartner R (1999) Prevention of osteoporosis after cardiac transplantation: a prospective, longitudinal, randomized, double-blind trial with calcitriol. Transplantation 68:523–530PubMedCrossRefGoogle Scholar
  81. 81.
    Kovac D, Lindic J, Kandus A, Bren AF (2001) Prevention of bone loss in kidney graft recipients. Transplant Proc 33:1144–1145PubMedCrossRefGoogle Scholar
  82. 82.
    Giannini S, Dangel A, Carraro G, Nobile M, Rigotti P, Bonfante L, Marchini F, Zaninotto M, Dalle Carbonare L, Sartori L, Crepaldi G (2001) Alendronate prevents further bone loss in renal transplant recipients. J Bone Miner Res 16:2111–2117PubMedCrossRefGoogle Scholar
  83. 83.
    Trabulus S, Altiparmak MR, Apaydin S, Serdengecti K, Sariyar M (2008) Treatment of renal transplant recipients with low bone mineral density: a randomized prospective trial of alendronate, alfacalcidol, and alendronate combined with alfacalcidol. Transplant Proc 40:160–166PubMedCrossRefGoogle Scholar
  84. 84.
    Coco M, Glicklich D, Faugere MC, Burris L, Bognar I, Durkin P, Tellis V, Greenstein S, Schechner R, Figueroa K, McDonough P, Wang G, Malluche H (2003) Prevention of bone loss in renal transplant recipients: a prospective, randomized trial of intravenous pamidronate. J Am Soc Nephrol 14:2669–2676PubMedCrossRefGoogle Scholar
  85. 85.
    Crawford BA, Kam C, Pavlovic J, Byth K, Handelsman DJ, Angus PW, McCaughan GW (2006) Zoledronic acid prevents bone loss after liver transplantation: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 144:239–248PubMedGoogle Scholar
  86. 86.
    Vieth R (2007) Vitamin D toxicity, policy, and science. J Bone Miner Res 22(Suppl 2):V64–V68PubMedCrossRefGoogle Scholar
  87. 87.
    Breen TL, Shane E (2004) Prolonged hypocalcemia after treatment with zoledronic acid in a patient with prostate cancer and vitamin D deficiency. J Clin Oncol 22:1531–1532PubMedCrossRefGoogle Scholar
  88. 88.
    Bikle DD (2008) Vitamin D and the immune system: role in protection against bacterial infection. Curr Opin Nephrol Hypertens 17:348–352PubMedCrossRefGoogle Scholar
  89. 89.
    Adams JS, Hewison M (2010) Update in vitamin D. J Clin Endocrinol Metab 95:471–478PubMedCrossRefGoogle Scholar
  90. 90.
    Peric M, Koglin S, Kim SM, Morizane S, Besch R, Prinz JC, Ruzicka T, Gallo RL, Schauber J (2008) IL-17A enhances vitamin D3-induced expression of cathelicidin antimicrobial peptide in human keratinocytes. J Immunol 181:8504–8512PubMedGoogle Scholar
  91. 91.
    Schauber J, Oda Y, Buchau AS, Yun QC, Steinmeyer A, Zugel U, Bikle DD, Gallo RL (2008) Histone acetylation in keratinocytes enables control of the expression of cathelicidin and CD14 by 1,25-dihydroxyvitamin D3. J Invest Dermatol 128:816–824PubMedCrossRefGoogle Scholar
  92. 92.
    Liu N, Nguyen L, Chun RF, Lagishetty V, Ren S, Wu S, Hollis B, DeLuca HF, Adams JS, Hewison M (2008) Altered endocrine and autocrine metabolism of vitamin D in a mouse model of gastrointestinal inflammation. Endocrinology 149:4799–4808PubMedCrossRefGoogle Scholar
  93. 93.
    Hansdottir S, Monick MM, Hinde SL, Lovan N, Look DC, Hunninghake GW (2008) Respiratory epithelial cells convert inactive vitamin D to its active form: potential effects on host defense. J Immunol 181:7090–7099PubMedGoogle Scholar
  94. 94.
    Cantorna MT, Hullett DA, Redaelli C, Brandt CR, Humpal-Winter J, Sollinger HW, Deluca HF (1998) 1,25-Dihydroxyvitamin D3 prolongs graft survival without compromising host resistance to infection or bone mineral density. Transplantation 66:828–831PubMedCrossRefGoogle Scholar
  95. 95.
    Ginde AA, Mansbach JM, Camargo CA Jr (2009) Association between serum 25-hydroxyvitamin D level and upper respiratory tract infection in the Third National Health and Nutrition Examination Survey. Arch Intern Med 169:384–390PubMedCrossRefGoogle Scholar
  96. 96.
    Zhang AB, Zheng SS, Jia CK, Wang Y (2003) Effect of 1,25-dihydroxyvitamin D3 on preventing allograft from acute rejection following rat orthotopic liver transplantation. World J Gastroenterol 9:1067–1071PubMedGoogle Scholar
  97. 97.
    Redaelli CA, Wagner M, Tien YH, Mazzucchelli L, Stahel PF, Schilling MK, Dufour JF (2001) 1 alpha, 25-Dihydroxycholecalciferol reduces rejection and improves survival in rat liver allografts. Hepatology 34:926–934PubMedCrossRefGoogle Scholar
  98. 98.
    Becker BN, Hullett DA, O’Herrin JK, Malin G, Sollinger HW, DeLuca H (2002) Vitamin D as immunomodulatory therapy for kidney transplantation. Transplantation 74:1204–1206PubMedCrossRefGoogle Scholar
  99. 99.
    Hullett DA, Cantorna MT, Redaelli C, Humpal-Winter J, Hayes CE, Sollinger HW, Deluca HF (1998) Prolongation of allograft survival by 1,25-dihydroxyvitamin D3. Transplantation 66:824–828PubMedCrossRefGoogle Scholar
  100. 100.
    Tanaci N, Karakose H, Guvener N, Tutuncu NB, Colak T, Haberal M (2003) Influence of 1,25-dihydroxyvitamin D3 as an immunomodulator in renal transplant recipients: a retrospective cohort study. Transplant Proc 35:2885–2887PubMedCrossRefGoogle Scholar
  101. 101.
    Ahmadpoor P, Ilkhanizadeh B, Ghasemmahdi L, Makhdoomi K, Ghafari A (2009) Effect of active vitamin D on expression of co-stimulatory molecules and HLA-DR in renal transplant recipients. Exp Clin Transplant 7:99–103PubMedGoogle Scholar
  102. 102.
    National Kidney Foundation (2003) K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 42:1–201Google Scholar
  103. 103.
    Lappe JM, Travers-Gustafson D, Davies KM, Recker RR, Heaney RP (2007) Vitamin D and calcium supplementation reduces cancer risk: results of a randomized trial. Am J Clin Nutr 85:1586–1591PubMedGoogle Scholar
  104. 104.
    Wactawski-Wende J, Kotchen JM, Anderson GL, Assaf AR, Brunner RL, O’Sullivan MJ, Margolis KL, Ockene JK, Phillips L, Pottern L, Prentice RL, Robbins J, Rohan TE, Sarto GE, Sharma S, Stefanick ML, Van Horn L, Wallace RB, Whitlock E, Bassford T, Beresford SA, Black HR, Bonds DE, Brzyski RG, Caan B, Chlebowski RT, Cochrane B, Garland C, Gass M, Hays J, Heiss G, Hendrix SL, Howard BV, Hsia J, Hubbell FA, Jackson RD, Johnson KC, Judd H, Kooperberg CL, Kuller LH, LaCroix AZ, Lane DS, Langer RD, Lasser NL, Lewis CE, Limacher MC, Manson JE (2006) Calcium plus vitamin D supplementation and the risk of colorectal cancer. N Engl J Med 354:684–696PubMedCrossRefGoogle Scholar
  105. 105.
    Pilz S, Dobnig H, Fischer JE, Wellnitz B, Seelhorst U, Boehm BO, Marz W (2008) Low vitamin D levels predict stroke in patients referred to coronary angiography. Stroke 39:2611–2613PubMedCrossRefGoogle Scholar
  106. 106.
    Pilz S, Marz W, Wellnitz B, Seelhorst U, Fahrleitner-Pammer A, Dimai HP, Boehm BO, Dobnig H (2008) Association of vitamin D deficiency with heart failure and sudden cardiac death in a large cross-sectional study of patients referred for coronary angiography. J Clin Endocrinol Metab 93:3927–3935PubMedCrossRefGoogle Scholar
  107. 107.
    Dobnig H, Pilz S, Scharnagl H, Renner W, Seelhorst U, Wellnitz B, Kinkeldei J, Boehm BO, Weihrauch G, Maerz W (2008) Independent association of low serum 25-hydroxyvitamin D and 1,25-dihydroxyvitamin d levels with all-cause and cardiovascular mortality. Arch Intern Med 168:1340–1349PubMedCrossRefGoogle Scholar
  108. 108.
    Autier P, Gandini S (2007) Vitamin D supplementation and total mortality: a meta-analysis of randomized controlled trials. Arch Intern Med 167:1730–1737PubMedCrossRefGoogle Scholar
  109. 109.
    Virtanen JK, Nurmi T, Voutilainen S, Mursu J, Tuomainen TP (2010) Association of serum 25-hydroxyvitamin D with the risk of death in a general older population in Finland. Eur J Nutr Oct 26. doi:10.1007/s00394-010-0138-3

Copyright information

© International Osteoporosis Foundation and National Osteoporosis Foundation 2010

Authors and Affiliations

  1. 1.Department of MedicineColumbia University Medical CenterNew YorkUSA

Personalised recommendations